Eupraxia’s CEO, Dr. James Helliwell, will be presenting on May 5th, 2025, at 3:30pm ET at the Bloom Burton & Co. Healthcare Investor Conference being held at the Metro Toronto Convention Centre, and ...

Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has shared an update. On April 24, 2025, Eupraxia Pharmaceuticals announced its participation in several ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

The National Institutes of Health has withdrawn renewal grant applications for the Consortium of Eosinophilic Gastrointestinal Disease Researchers. Patient advocacy organizations, including the ...